Please assess the completion status of the following clinical trial:

Trial Title: Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 and ≤ 70 years of age~* Histologically confirmed advanced or metastatic adenocarcinoma of the stomach~* Have failed for 2 lines of chemotherapy~* Life expectancy of more than 3 months~* ECOG performance scale ≤ 2~* At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)~* Duration from the last therapy is more than 6 weeks for nitroso or mitomycin~* More than 4 weeks for operation or radiotherapy~* More than 4 weeks for cytotoxic agents or growth inhibitors~* Adequate hepatic, renal, heart, and hematologic functions (platelets \> 80 × 109/L, neutrophil \> 2.0 × 109/L, serum creatinine ≤ 1.5mg/dl, total bilirubin within upper limit of normal(ULN), and serum transaminase≤2.5×the ULN).~Exclusion Criteria:~* Pregnant or lactating women~* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix~* Any factors that influence the usage of oral administration; Evidence of CNS metastasis~* History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix~* Intercurrence with one of the following: hypertension, coronary artery disease, arrhythmia and heart failure~* Receiving the therapy of thrombolysis or anticoagulation~* Abuse of alcohol or drugs~* Allergy to the ingredient of the agent or more than two kinds of food and drug~* Less than 4 weeks from the last clinical trial~* Disability of serious uncontrolled intercurrence infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A 850 (Type: EXPERIMENTAL): apatinib 850 mg qd, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
- B 425 (Type: EXPERIMENTAL): apatinib 425 mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
- C pla (Type: PLACEBO_COMPARATOR): placebo bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Based on this trial design, predict the completion outcome and termination type (if applicable).